PDF(Pubmed)
Abstract：
UNASSIGNED: The legalization of cannabis in Thailand has renewed interest in its traditional medical use. This study aimed to explore the prescribing patterns of traditional practitioners and assess the impact of cannabis oil on patients\' quality of life, with a specific focus on comparing outcomes between cancer and non-cancer patients.
UNASSIGNED: We conducted a prospective observational cohort study across 30 sites in 21 Thai provinces to analyze the use of \"Ganja Oil,\" a cannabis extract in 10% coconut oil, prescribed for symptoms like pain, anorexia, and insomnia across a diverse patient group, including cancer and migraines. Quality of life was assessed using the Edmonton Symptom Assessment Scale (ESAS) and EQ-5D-5L at baseline, 1, 2, and 3 months. The study included a predefined subgroup analysis to compare the effects on cancer versus non-cancer patients. Data management was facilitated through Research Electronic Data Capture (REDCap), with statistical analysis performed using Stata/MP.
UNASSIGNED: Among 21,284 participants, the mean age was 54.10 ± 15.32 years, with 52.49% being male. The baseline EQ-5D-5L index was 0.85 ± 0.24. Significant differences in EQ-5D-5L indices were seen between cancer patients (0.79 ± 0.32) and non-cancer patients (0.85 ± 0.23; p < 0.001). ESAS scores also differed significantly between these groups for all symptoms, except anxiety. The most frequent prescription of Ganja Oil was oral administration at bedtime (88.26%), with the predominant dosage being three drops daily, approximately 0.204 mg of tetrahydrocannabinol in total. Posttreatment, significant improvements were noted: the EQ-5D-5L index increased by 0.11 points (95% CI: 0.11, 0.11; p < 0.001) overall, 0.13 points (95% CI: 0.12, 0.14; p < 0.001) for cancer patients, and 0.11 points (95% CI: 0.10, 0.11; p < 0.001) for non-cancer patients. ESAS pain scores improved by -2.66 points (95% CI: -2.71, -2.61; p < 0.001) overall, -2.01 points (95% CI: -2.16, -1.87; p < 0.001) for cancer patients, and -2.75 points (95% CI: -2.80, -2.70; p < 0.001) for non-cancer patients, with similar significant improvements in other symptoms.
UNASSIGNED: Our study indicates potential benefits of Ganja Oil for improving quality of life among Thai patients, as a complementary treatment. These findings must be viewed in light of the study\'s design limitations. Further controlled studies are essential to ascertain its efficacy and inform dosing guidelines.
UNASSIGNED: We conducted a prospective observational cohort study across 30 sites in 21 Thai provinces to analyze the use of \"Ganja Oil,\" a cannabis extract in 10% coconut oil, prescribed for symptoms like pain, anorexia, and insomnia across a diverse patient group, including cancer and migraines. Quality of life was assessed using the Edmonton Symptom Assessment Scale (ESAS) and EQ-5D-5L at baseline, 1, 2, and 3 months. The study included a predefined subgroup analysis to compare the effects on cancer versus non-cancer patients. Data management was facilitated through Research Electronic Data Capture (REDCap), with statistical analysis performed using Stata/MP.
UNASSIGNED: Among 21,284 participants, the mean age was 54.10 ± 15.32 years, with 52.49% being male. The baseline EQ-5D-5L index was 0.85 ± 0.24. Significant differences in EQ-5D-5L indices were seen between cancer patients (0.79 ± 0.32) and non-cancer patients (0.85 ± 0.23; p < 0.001). ESAS scores also differed significantly between these groups for all symptoms, except anxiety. The most frequent prescription of Ganja Oil was oral administration at bedtime (88.26%), with the predominant dosage being three drops daily, approximately 0.204 mg of tetrahydrocannabinol in total. Posttreatment, significant improvements were noted: the EQ-5D-5L index increased by 0.11 points (95% CI: 0.11, 0.11; p < 0.001) overall, 0.13 points (95% CI: 0.12, 0.14; p < 0.001) for cancer patients, and 0.11 points (95% CI: 0.10, 0.11; p < 0.001) for non-cancer patients. ESAS pain scores improved by -2.66 points (95% CI: -2.71, -2.61; p < 0.001) overall, -2.01 points (95% CI: -2.16, -1.87; p < 0.001) for cancer patients, and -2.75 points (95% CI: -2.80, -2.70; p < 0.001) for non-cancer patients, with similar significant improvements in other symptoms.
UNASSIGNED: Our study indicates potential benefits of Ganja Oil for improving quality of life among Thai patients, as a complementary treatment. These findings must be viewed in light of the study\'s design limitations. Further controlled studies are essential to ascertain its efficacy and inform dosing guidelines.
摘要：
■泰国的大麻合法化重新引起了人们对其传统医学用途的兴趣。本研究旨在探索传统从业者的处方模式，并评估大麻油对患者生活质量的影响，特别关注比较癌症和非癌症患者的预后。
■我们在泰国21个省的30个地点进行了一项前瞻性观察性队列研究，以分析“GanjaOil”的使用情况，“10%椰子油中的大麻提取物，为疼痛等症状开处方，厌食症,以及不同患者群体的失眠，包括癌症和偏头痛.在基线时使用埃德蒙顿症状评估量表（ESAS）和EQ-5D-5L评估生活质量，1、2和3个月。该研究包括预定义的亚组分析，以比较对癌症与非癌症患者的影响。通过研究电子数据采集(REDCap)促进了数据管理，使用Stata/MP进行统计分析。
■在21,284名参与者中，平均年龄54.10±15.32岁,52.49%是男性。基线EQ-5D-5L指数为0.85±0.24。在癌症患者（0.79±0.32）和非癌症患者（0.85±0.23；p<0.001）之间，EQ-5D-5L指数存在显着差异。所有症状的ESAS评分在这些组间也有显著差异，除了焦虑.GanjaOil的最常见处方是在睡前口服（88.26％），主要剂量是每天三滴，总计约0.204mg四氢大麻酚。后处理,注意到显著改善：EQ-5D-5L指数总体上增加了0.11点（95％CI：0.11，0.11；p<0.001），癌症患者为0.13分（95％CI：0.12，0.14；p<0.001），非癌症患者为0.11分（95％CI：0.10，0.11；p<0.001）。ESAS疼痛评分总体改善-2.66分(95%CI:-2.71,-2.61;p<0.001),癌症患者的-2.01分（95％CI：-2.16，-1.87；p<0.001），和-2.75分（95%CI：-2.80，-2.70；p<0.001），其他症状也有类似的显著改善。
■我们的研究表明，GanjaOil对改善泰国患者的生活质量具有潜在的益处。作为补充治疗。这些发现必须根据研究的设计限制来看待。进一步的对照研究对于确定其功效和告知给药指南至关重要。
■我们在泰国21个省的30个地点进行了一项前瞻性观察性队列研究，以分析“GanjaOil”的使用情况，“10%椰子油中的大麻提取物，为疼痛等症状开处方，厌食症,以及不同患者群体的失眠，包括癌症和偏头痛.在基线时使用埃德蒙顿症状评估量表（ESAS）和EQ-5D-5L评估生活质量，1、2和3个月。该研究包括预定义的亚组分析，以比较对癌症与非癌症患者的影响。通过研究电子数据采集(REDCap)促进了数据管理，使用Stata/MP进行统计分析。
■在21,284名参与者中，平均年龄54.10±15.32岁,52.49%是男性。基线EQ-5D-5L指数为0.85±0.24。在癌症患者（0.79±0.32）和非癌症患者（0.85±0.23；p<0.001）之间，EQ-5D-5L指数存在显着差异。所有症状的ESAS评分在这些组间也有显著差异，除了焦虑.GanjaOil的最常见处方是在睡前口服（88.26％），主要剂量是每天三滴，总计约0.204mg四氢大麻酚。后处理,注意到显著改善：EQ-5D-5L指数总体上增加了0.11点（95％CI：0.11，0.11；p<0.001），癌症患者为0.13分（95％CI：0.12，0.14；p<0.001），非癌症患者为0.11分（95％CI：0.10，0.11；p<0.001）。ESAS疼痛评分总体改善-2.66分(95%CI:-2.71,-2.61;p<0.001),癌症患者的-2.01分（95％CI：-2.16，-1.87；p<0.001），和-2.75分（95%CI：-2.80，-2.70；p<0.001），其他症状也有类似的显著改善。
■我们的研究表明，GanjaOil对改善泰国患者的生活质量具有潜在的益处。作为补充治疗。这些发现必须根据研究的设计限制来看待。进一步的对照研究对于确定其功效和告知给药指南至关重要。
